Order Code CFSMN Cystic Fibrosis and Spinal Muscular Atrophy Carrier Screen Panel, Varies
Ordering Guidance
This test is specifically for carrier screening purposes and is not intended for diagnostic purposes. For diagnostic testing, order CFMP / Cystic Fibrosis, CFTR Gene, Variant Panel, Varies.
If the reproductive partner is also having this test performed, call the lab for a revised risk assessment.
Targeted testing for familial variants (also called site-specific or known mutation testing) is available for all genes on this panel under FMTT / Familial Variant, Targeted Testing, Varies. Call 800-533-1710 to obtain more information about this testing option.
Shipping Instructions
Specimen preferred to arrive within 96 hours of collection.
Necessary Information
If there is a family history of cystic fibrosis (CF) or spinal muscular atrophy (SMA), the known genetic variant in the family should be supplied for best interpretation of results.
Specimen Required
Specimen Type: Whole blood
Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.
Container/Tube:
Preferred: Lavender top (EDTA) or yellow top (ACD)
Acceptable: Any anticoagulant
Specimen Volume: 3 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
Additional Information: To ensure minimum volume and concentration of DNA is met, the preferred volume of blood must be submitted. Testing may be canceled if DNA requirements are inadequate.
Forms
1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available:
-Informed Consent for Genetic Testing (T576)
-Informed Consent for Genetic Testing-Spanish (T826)
2. Molecular Genetics: Congenital Inherited Diseases Patient Information (T521) Â
Useful For
Reproductive risk refinement via carrier screening for individuals in the general population for cystic fibrosis and spinal muscular atrophy.
Â
Reproductive risk refinement via carrier screening for individuals with a family history of cystic fibrosis and/or spinal muscular atrophy when familial variants are not available
This test is not useful for clinical diagnosis of an affected individual.
Genetics Test Information
This test includes targeted testing to evaluate over 500 genetic variants including the 23 cystic fibrosis transmembrane conductance regulator (CFTR) variants recommended by the American College of Medical Genetics and Genomics as well as targeted testing of survival motor neuron 1 (SMN1) and SMN2.
Special Instructions
Method Name
Targeted Genotyping Array
Reporting Name
CF and SMA Carrier Screen PanelSpecimen Type
VariesSpecimen Minimum Volume
1 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Varies | Ambient (preferred) | ||
Frozen | |||
Refrigerated |
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Reference Values
An interpretive report will be provided.
Method Description
The targeted genotyping array utilizing the ThermoFisher GeneTitan platform is used to detect select genetic variants in the following genes associated with heritable conditions: cystic fibrosis transmembrane conductance regulator (CFTR) and survival motor neuron 1 (SMN1). SMN2 may be reported in conjunction with relevant genotype findings.
For details regarding the targeted mutations identified by this test see Targeted Variants Detected by Focused Carrier Screening Tests.
Multiplex ligation-dependent probe amplification, polymerase chain reaction (PCR), relative quantitative PCR, droplet digital PCR, and Sanger sequencing are used to confirm alterations detected by microarray when appropriate.(Unpublished Mayo method)
Day(s) Performed
Thursday, Sunday
Performing Laboratory
Mayo Clinic Laboratories in RochesterCPT Code Information
81220
81329
81222
81479 (if appropriate for government payers)